Clinical Data

Eight clinical studies with lasmiditan have been completed.

Formulation

Phase

Study Objectives

Downloads

IV Infusion

1

Safety, Tolerability & PK

 

Oral Solution and Sublingual

1

Safety, Tolerability & PK

Download

Oral Solution and Oral Tablet

1

Bioavailability and Pharmacokinetics

Download

Oral Tablet

1

TQT study

Download

Oral Tablet

1

Bioavailability under fed and fasted conditions

Link

IV Infusion

2

Efficacy and safety of a range of intravenous doses

Download

Oral Tablet

2b

Efficacy and safety of a range of oral doses

Download

Oral Tablet

 3

SAMURAI (Pivotal)

 

Top Line Data

Secondary Endpoints

Onset of Action

Oral Tablet

 3

SPARTAN (Pivotal)

 

Enrollment Update

Link

Oral Tablet

 3

GLADIATOR (Long-term Safety)

 

SAMURAI Results and Gladiator Update

EHMTIC GLADIATOR Presentation

Link

More information about our clinical trials program can be found at clinicaltrials.gov.

The Future of Migraine

The Future of Migraine

Lasmiditan is an innovative therapy in development by CoLucid, the first from a novel drug class called “ditans.”

Unlike triptans, lasmiditan penetrates the centeral nervous system (CNS) and selectively targets 5‑HT1F receptors expressed in the trigeminal nerve pathway to offer effective treatment for migraine through a non-vasoconstrictive mechanism of action.

Migraine is a Serious Neurological Disease

Migraine is a Serious Neurological Disease

Migraine is more than headache pain. Migraine has multiple symptoms, which may include extreme sensitivity to light and sound, as well as nausea. A migraine attack can last from several hours to several days and severely impair daily function. Migraine can continue over a lifetime.

Learn More